Rifabutin indications and usage: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{Rifabutin }} {{CMG}}; {{AE}} {{chetan}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MYCOBUTIN (RIFABUTIN) CAPSULE [PHARMACIA A..." |
Gerald Chi (talk | contribs) mNo edit summary |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Rifabutin }} | {{Rifabutin}} | ||
{{CMG}}; {{AE}} {{ | {{CMG}}; {{AE}} {{Chetan}} | ||
==Indications and Usage== | |||
MYCOBUTIN Capsules are indicated for the prevention of disseminated ''[[Mycobacterium avium complex]]'' (MAC) disease in patients with advanced [[HIV]] infection.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MYCOBUTIN (RIFABUTIN) CAPSULE [PHARMACIA AND UPJOHN COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e1a6613-bdd3-4261-93b3-d7f5cc09064b | publisher = | date = | accessdate }}</ref> | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MYCOBUTIN (RIFABUTIN) CAPSULE [PHARMACIA AND UPJOHN COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e1a6613-bdd3-4261-93b3-d7f5cc09064b | publisher = | date = | accessdate }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 03:12, 4 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Indications and Usage
MYCOBUTIN Capsules are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection.[1]
References
- ↑ "MYCOBUTIN (RIFABUTIN) CAPSULE [PHARMACIA AND UPJOHN COMPANY]". Text " accessdate " ignored (help)
Adapted from the FDA Package Insert.